leadf
logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals signs partnership to launch international medicinal cannabis research hub

CannaHub is a new addition to the MGC projects currently underway with the Royal Melbourne Institute of Technology, and will be formally launched in Q1 2019.

cannabis
MGC holds the first right to use or acquire all data, technology, or findings generated

MGC Pharmaceuticals Ltd (ASX:MXC) has signed a binding partnership agreement with the Royal Melbourne Institute of Technology (RMIT) and The Hebrew University of Jerusalem (HUJ) to form a joint international medical research hub for medicinal cannabis innovation and technologies.

As an extension to MGC’s existing collaboration with RMIT, the new research hub, to be known as CannaHub, is a collaborative centre between MGC, RMIT and HUJ and will be an international shared library of research, data and analytics on medicinal cannabis and its uses including future medical applications and treatments.

The agreement represents a landmark achievement for MGC. The formation of CannaHub is the first time RMIT or HUJ has partnered with a private company to form a research institute in this sector.

READ: MGC Pharmaceuticals rockets up 37% after reimbursement win for cannabis epilepsy therapeutic

CannaHub’s research projects will initially focus on three key areas in the use of medicinal cannabis, being the treatment of cancer, the effectiveness of traditional and medicinal cannabis combination treatments and drug delivery systems with technological elements.

Importantly, the results from the research project is expected to strategically position MGC as a leader in the cancer research and technology-based drug delivery space, enabling the company to develop and leverage its commercial interllectual property (IP) for the production of new medicinal cannabis products, applications and technologies.

MGC co-founder and managing director Roby Zomer said: “We are very pleased to announce the completion of our formal collaboration and partnership agreement with RMIT and HUJ to launch CannaHub.

“CannaHub is designed to advance world leading research and push forward innovation within the medicinal cannabis pharmaceutical market.

“We look forward to working with the teams at RMIT and HUJ and delivering ground breaking results in the future.”

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.021 AUD

ASX:MXC
Market: ASX
Market Cap: $35.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: THC Global Group granted GMP Licence for Southport cannabis...

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA). This milestone...

on 28/1/20

2 min read